1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Incyte Corporation

Incyte Corporation

INCY
Incyte CorporationUS flagNASDAQ Global Select
113.27
USD
+1.70
- -
22.96BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.39
3.05
4.2
5.89
7.51
8.86
10.04
12.23
13.55
15.29
16.53
20.48
26.34
29.36
Basic EPS, GAAP
-0.56
-0.29
0.04
0.55
-1.53
0.52
2.08
-1.36
4.3
1.53
2.67
0.16
6.59
8.13
Free Cash Flow per Basic Share
0.06
0.16
0.5
1.62
-0.45
1.58
3.31
-0.57
3.4
4.37
2.15
1.55
7.11
9.84
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-1.18
-0.48
0.92
2.22
7.72
9.03
12.02
11.9
17.05
19.62
23.14
17.82
26.04
31.57
Tangible Book Value per Share
-1.18
-0.48
0.92
-0.03
5.86
7.29
10.4
10.4
15.67
18.34
21.89
16.43
24.78
30.39
Basic Weighted Avg Shares
148
168
180
188
205
212
215
218
220
222
224
207
195
198
Sales/Revenue/Turnover
355
511
754
1,106
1,536
1,882
2,159
2,667
2,986
3,395
3,696
4,241
5,141
5,820
Operating Margin (%)
-4.54
-0.94
6.72
14.69
-15.34
8.26
19.53
-9.01
20.11
17.43
17.73
2.39
26.12
31.61
Depreciation Expense
29
41
45
58
52
55
55
52
58
68
83
89
93
98
Net Income, GAAP
-83
-48
7
104
-313
109
447
-296
949
341
598
33
1,287
1,612
Effective Tax Rate (%)
- -
- -
13.57
2.96
- -
5.08
8.19
- -
- -
35.62
28.36
89.7
22.7
18.04
Profit Margin (%)
-23.43
-9.48
0.87
9.43
-20.38
5.82
20.7
-11.09
31.76
10.04
16.17
0.77
25.03
27.71
Working Capital
448
459
674
721
1,129
1,407
1,968
1,729
2,264
2,936
3,405
1,597
3,509
4,714
LT Debt
662
590
620
651
17
17
32
33
32
30
29
34
30
28
Total Equity
-193
-82
171
419
1,631
1,926
2,598
2,611
3,770
4,370
5,190
3,448
5,167
6,344
Return on Invested Capital (%)
- -
- -
6.32
16.93
- -
8.16
16.76
- -
- -
9.25
9.69
0.24
23.79
28.44
Return on Capital (%)
- -
- -
6.64
15.23
- -
6.14
19.42
- -
- -
8.32
12.44
0.75
29.62
30.47
Return on Common Equity (%)
- -
- -
- -
35.29
-30.55
6.16
19.76
-11.35
29.73
8.37
12.5
0.76
29.87
30.67

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
10
10
10
LT Borrowings
- -
- -
- -
LT Finance Leases
30
29
28
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
198
200
201
Market Capitalization
19,602
18,819
22,783

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
5,024
5,484
6,027
Cash, Cash Equivalents & STI
3,581
4,016
4,536
Accounts Receivable, Net
1,024
1,051
1,125
Inventories
101
116
113
Total Current Liabilities
1,515
1,490
1,312
Payables & Accruals
503
514
520
ST Debt
10
10
10
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
58.27%
19.07%
49.89%
Free Cash Flow
-78.11%
-84.75%
331.97%
Net Income, GAAP
444.33%
668.19%
3,844.96%
Sales/Revenue/Turnover
21.69%
14.1%
21.22%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
881
1,044
1,138
1,179
4,241
2025
1,053
1,216
1,366
1,507
5,141
2026
1,273
1,674
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.76
-2.04
0.55
1.04
0.16
2025
0.82
2.09
2.17
1.52
6.59
2026
1.52
2.92
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
William J. Meury
Full Time Employees
2,844
Sector
Healthcare
Industry
Biotechnology
Address
1801 Augustine Cut-Off Wilmington DE United States of America 19803
IPO Date
Nov 4, 1993
CIK
0000879169
Website
incyte.com
Similar Companies
Kinnate Biopharma Inc. (KNTE)
Alterity Therapeutics Limited (PRNAF)
Erasca, Inc. (ERAS)
Eliem Therapeutics, Inc. (ELYM)
Alumis Inc. (ALMS)
Predictive Technology Group, Inc. (PRED)
Business
Incyte Corporation (INCY) is a Wilmington, Delaware-based biopharmaceutical company founded in 2002 that discovers, develops, and commercializes proprietary medicines for oncology, inflammation, autoimmunity, and dermatology; it operates globally in North America, Europe, and Asia with over 2,500 employees focused on unmet medical needs. The company markets a diversified portfolio of approved products including Jakafi (ruxolitinib) for myelofibrosis, polycythemia vera, and graft-versus-host disease; Opzelura (ruxolitinib) cream for atopic dermatitis and vitiligo; Pemazyre (pemigatinib) for cholangiocarcinoma and myeloid/lymphoid neoplasms; Monjuvi (tafasitamab-cxix) for relapsed or refractory diffuse large B-cell lymphoma; Tabrecta (capmatinib) for non-small cell lung cancer; Iclusig (ponatinib) for leukemia; and Olumiant (baricitinib) for rheumatoid arthritis and alopecia areata; it also advances a robust pipeline of clinical candidates discovered in-house targeting immunology, hematology-oncology, and inflammatory skin conditions. Recent developments include the 2024 acquisition of Escient Pharmaceuticals for $750 million to add first-in-class oral MRGPRX2 antagonists EP262 for hidradenitis suppurativa, prurigo nodularis, and other pruritic skin diseases and EP547 for pruritus in kidney and liver diseases; FDA approval of Niktimvo (axatilimab-csfr) with partner Syndax Pharmaceuticals in August 2024 for chronic graft-versus-host disease; relocation of over 300 Pennsylvania jobs to expanded downtown Wilmington headquarters by 2026 supporting more than 500 positions; and a 2025 roadmap featuring four potential product launches such as ruxolitinib XR and povorcitinib expansions, four pivotal trial readouts, seven proof-of-concept disclosures, and at least three Phase 3 initiations toward over 10 high-impact launches by 2030.

Company News

Company News APIChatGPT

  • businesswire.com

    Incyte Honors the 2026 MPN Heroes®, Celebrating Champions of the Myeloproliferative Neoplasm (MPN) Community

  • gurufocus.com

    Incyte to Report Third Quarter Financial Results

  • businesswire.com

    Incyte to Report Third Quarter Financial Results

  • globenewswire.com

    Knight Therapeutics Announces Regulatory Approval of NIKTIMVO® in Brazil

  • zacks.com

    INCY or TECH: Which Is the Better Value Stock Right Now?

  • zacks.com

    MIRM Secures FDA Nod for an Ultra-Rare Bone Disorder Therapy

  • prnewswire.com

    MiniMed appoints Sheila Denton as General Counsel & Corporate Secretary

  • businesswire.com

    Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva

  • businesswire.com

    Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte's Inflammation and Autoimmunity Portfolio

  • zacks.com

    Is First Trust Large Cap Growth AlphaDEX ETF (FTC) a Strong ETF Right Now?

  • defenseworld.net

    Incyte Maps Post-JAKAFI Growth With Pipeline Push and $4B Sales Target

  • prnewswire.com

    Specialised Therapeutics Expands Partnership with Incyte to Include Ruxolitinib Cream (Opzelura®) in Australia

  • marketbeat.com

    Incyte Maps Post-JAKAFI Growth With Pipeline Push and $4B Sales Target

  • seekingalpha.com

    Incyte Corporation (INCY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

  • zacks.com

    These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

  • defenseworld.net

    Integrated Wealth Concepts LLC Sells 5,987 Shares of Incyte Corporation $INCY

  • zacks.com

    INCY Stock Gains 23% Year to Date: Buy, Sell or Hold?

  • seekingalpha.com

    Incyte Corporation (INCY) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

  • seekingalpha.com

    Incyte Corporation (INCY) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

  • zacks.com

    Should First Trust Large Cap Growth AlphaDEX ETF (FTC) Be on Your Investing Radar?